Last reviewed · How we verify
autologous cord blood stem cell — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
autologous cord blood stem cell (autologous cord blood stem cell) — Assistance Publique Hopitaux De Marseille.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| autologous cord blood stem cell TARGET | autologous cord blood stem cell | Assistance Publique Hopitaux De Marseille | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- autologous cord blood stem cell CI watch — RSS
- autologous cord blood stem cell CI watch — Atom
- autologous cord blood stem cell CI watch — JSON
- autologous cord blood stem cell alone — RSS
Cite this brief
Drug Landscape (2026). autologous cord blood stem cell — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-cord-blood-stem-cell. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab